Yoon et al. reported that NF1 gene product neurofibromin negatively regulated Ras and mammalian target of rapamycin (mTOR) signaling and prompted clinical trials to evaluate the ability of Ras and mTOR pathway inhibitors to arrest NF1-associated tumor growth [24]. The gene discussed is MTOR; the disease is neoplasm.